Enterprise League logo

Biotechnology Companies in Europe

Biotechnology companies develop, manufacture, and distribute medical devices, diagnostics, or pharmaceutical products for use in clinical, hospital, and research settings. This page lists companies operating in the Biotechnology sector based on self-reported profile data. The directory currently holds 480 companies in this sector. The largest share of listings is based in London. Related sectors on Enterprise League include Medical Equipment and Services, Life Science, Genetics, Pharmaceutical, Biopharma, Clinical Trials, Nanotechnology.
480 companies
London top city

Europe
Biotechnology
List of Biotechnology companies in Europe

480 companies

Sort by

Atlantic Instrument For Research (AI4R) is the world leader in digital real-time autoradiography, a new-generation imaging solutions for preclinical studies. Our company has designed a new autoradiograph: the BeaQuant. Our device uses an innovative technology (gaz detection) to give researchers a quantitative mapping of radioactivity in a sample (alpha and beta radioisotopes) . Users will experience the highest resolution in the market for autoradiographic analysis, shorter acquisition time, complete safety and unique versatility (with features such as: QWBA or dual-isotope analysis). The BeaQuant is the perfect tool to establish in vitro–in vivo correlation. If you are interested in learning more about our technology, please feel free to visit our website and contact us!
Medical
Biotechnology

2012

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis, across a variety of fields from oncology to neuroscience and more. From empowering researchers in the identification of novel biomarkers of disease, and supporting R&D scientists in speeding up time-to-market of novel drugs, to helping pathologists enhance the accuracy of cancer diagnostics — Aiforia has the expertise and experience to transform healthcare all the way from discovery to diagnosis.
Mental Health Care
IT Services
Machine learning
Artificial Intelligence
IT Consulting Services
Software
Healthcare

2013

Alkermes focuses on the development of innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction, and cancer. As a fully-integrated, global biopharmaceutical company, we apply our scientific expertise and proprietary technologies to develop products that are designed to make a meaningful difference in the way patients manage their disease. We are inspired by some of the most pressing public health challenges of our time to help advance innovation with the potential to improve treatment options and outcomes for patients. Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers, and broader impacted communities. In this context we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and awareness, and advocacy for important policies that support equitable access to quality treatment. Headquartered in Dublin, Ireland, we have an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines
Pharmaceutical
Healthcare
Biotechnology

1987

Allero Therapeutics is a Dutch, venture-backed, biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.
Pharmaceutical
Biotechnology

2016

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.
Medical
Pharmaceutical
Biopharma
Healthcare
Biotechnology
Life Science

2010

APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Biotechnology
Therapeutics
Life Science

2003

Apoglyx is a pre-clinical stage biotech company with the aim to develop a small molecule therapy for sepsis, and further indications, based on inhibition of Aquaporin-9. Apoglyx was founded based on research from Aarhus University (DK), Aalborg University (DK), and Lund University (S).
Biotechnology

2015

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.
Pharmaceutical
Biopharma
Biotechnology

2015

Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. With a unique proprietary technology that preclude the use of experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an exhaustive number of new drug candidates. We are hiring! Check our career website: https://jobs.lever.co/aqemia.com Blog Posts on: https://medium.com/aqemia
Machine learning
Artificial Intelligence
Pharmaceutical
Biotechnology
Quantum Computing

2019

ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role. The first investigational product from this platform is ATX-01, an antimiR in preclinical development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. To learn more about Arthex Biotech, please visit us at www.arthexbiotech.com
Biotechnology

2019

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.
Biotechnology
Therapeutics

2018

Who we are: atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. Our vision: To heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Our approach: By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.
Healthcare
Biotechnology
Therapeutics
Life Science

2018

b.fab is specialized in the efficient conversion of CO2 and hydrogen (H2) from renewable energy into biotechnological value chains. CO2 and water are abundantly available and therefore it is our starting point to build a sustainable bioeconomy. We use formate as our central mediator to bind and store CO2 and H2 (made from water) in liquid form. Our bioprocesses start with the feedstock formate and we use Synthetic Biology to design specific pathways and to convert formate into value-added chemicals. Our platform is build on anaerobic and aerobic microbial production hosts to provide flexibility in the process design and adaptation to specific product requirements. We apply laboratory automation, high-throughput experimentation and advanced bioprocess development in an agile environment to develop new bioprocesses efficiently and in a minimal time frame. b.fab is dedicated to establish a Formate Bioeconomy in the coming years, and thus, providing an economical and sustainable new way to produce value-added chemicals for various industries.
Sustainability
Biotechnology
Life Science

2018

BIOCAPTIVA is developing the BioCaptis, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. The BioCaptis captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BIOCAPTIVA was founded in 2021 when it spun out from the University of Edinburgh. BIOCAPTIVA is based in Edinburgh and backed by Archangels Scottish Enterprise, Cancer Research Horizons, the new innovation engine of Cancer Research UK and Old College Capital, the University of Edinburgh’s in-house venture investment fund. For more information, please visit www.biocaptiva.com
Medical Equipment and Services
Health and Medical Products
Medical
Healthcare
Biotechnology

2018

Biocellvia is a french company developing Intelligent Image Analysis solutions for pharmaceutical industry (Big Pharma, Biotechs, CRO) and academic communities involved in R&D. We have developed digital image analysis solutions, that enable to evaluate fully-automatically the level of efficacy of your lead molecules thanks to histological slides (in vitro, ex vivo, biopsies) in various pathologies such as: - Gastrointestinal (NASH, Liver fibrosis) - Respiratory (IPF, COPD, PAH) We provide image analysis as a service. Our technology evaluates your molecules with more accuracy, more reliability, more rapidity and less variability than traditional scoring methods. A full study (about 200 images) is performed in only a couple of days. http://biocellvia.com http://linkedin.com/company/biocellvia
Pharmaceutical
Biotechnology

2011

Biomemory creates DNA Drives for large corporates and administrations. We organize and store data on biocompatible DNA molecules.
Consumer Electronics
Data Center
Data Storage
Biotechnology

2021

New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine.
Medical Equipment and Services
Health and Medical Products
Medical
Pharmaceutical
Biotechnology
Commercial

2010

Blueprint Genetics is a genetic diagnostics company based in Helsinki, Seattle and Dubai. We provide world-class genetic diagnostics and clinical interpretation for hereditary diseases. We are passionate about changing peoples’ lives through development of groundbreaking solutions that take genetic diagnostics from niche to mainstream. Our global team of innovative and motivated people are working at the forefront of genetic knowledge, AI and other areas of life science. Our team consists of more than 20 nationalities working as geneticists, data analysts, laboratory technicians, client service specialists, genetic services consultants, software developers and marketing specialists. Today, we work with customers in over 70 countries and push to make genetic knowledge easier to access for the medical community. Our comprehensive and cost-effective genetic tests support healthcare professionals around the world in providing the best care for patients and families with rare inherited diseases.
Health Centers
Mental Health Care
Health and Medical Products
Personal Health
Healthcare
Biotechnology
Hospital

2012

We are interested in developing innovative hydrogels which will help shape the future of agriculture, environment and healthcare!
Biotechnology

2018

Relation is pioneering a “Lab-in-the-Loop” that can integrate active learning at every step of drug discovery, from predicting cell states to the validation of new targets. An important challenge for any therapeutics company using machine learning is “ground-truth data,” or information known to be true. Working from real cells provided by proprietary biobanks, Relation’s technology generates genomic data that provide direct insights into critical biological relationships that are fed directly into its ML systems. The platform then requests new experiments to improve its predictive ability, cutting through an otherwise intractable combinatorial space.
Medical
Healthcare
Biotechnology
Genetics

2019

Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every industry. We do this by creating the most general and efficient technology platform for chemical production that the world has ever seen. That’s a big claim, but we can stand behind it. By bio-upgrading the chemical industry with our cell-free biomanufacturing platform, we can produce the products that modern society relies on in a truly sustainable way. The technology platform utilises nature’s catalysts, enzymes, by combining the power of biology with the efficiency of the chemical industry in a best-of-both-worlds solution. EnginZyme is recognised as a Technology Pioneer by World Economic Forum and backed by Sofinnova Partners, Industrifonden, SEB Greentech VC, Bunge Ventures, Almi Invest GreenTech Fund, and Navigare Ventures.
Manufacturing
GreenTech
Biotechnology
Life Science

2014

ENOUGHs purpose to ‘make protein sustainable’. Using fermentation to meet future food protein needs is widely recognised as the most effective solution to feed a growing planet. ENOUGH produces ABUNDA® mycoprotein, a complete food ingredient containing all essential amino acids as well as being high in dietary fibre. It is versatile and can be made into alternative/vegan meat, seafood and dairy products. The company will supply ABUNDA as a B2B (business to business) food ingredient to consumer brands and retailers, addressing the need for high scale supply of healthy and sustainable protein to address a rapidly growing market. The impact of introducing 1 million tonnes of ABUNDA mycoprotein by 2032 is equivalent to replacing 5 million cows, over a 1 billion chickens and reducing more than 5 million tonnes of CO2 emissions.
IT Services
IT Consulting Services
Food Processing
Food Vendors
3D Technology
Biotechnology

2015

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).
Medical
Biopharma
Healthcare
Biotechnology

2004

EUCODIS Bioscience is a leading provider of novel industrial enzymes, with customers in the pharmaceutical, biotechnology, diagnostics, and other industries worldwide. With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes EUCODIS Bioscience has a proven track record of providing customized enzyme solutions. In addition, EUCODIS Bioscience provides services ranging from enzyme engineering to process development as well as protein manufacturing according to our customers' individual specifications. EUCODIS Bioscience provides customized services in recombinant protein and enzyme production by covering the whole spectrum of bioprocess development up to industrial-scale manufacture of your target proteins under ISO9001. Our headquarters and main laboratories are located at the Campus Vienna Biocenter, Austria’s largest Biotech and University cluster.
Cosmetics
Medical Equipment and Services
Health and Medical Products
Medical
Biopharma
Biotechnology

2007

Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients. The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.
Pharmaceutical
Healthcare
Biotechnology
Therapeutics

1993

ExactCure provides a personalized eHealth software solution. Our VISION is to live in a world where each individual has access to a personalized medication. Our MISSION is to predict the personalized effects and interactions of drugs within the body of each individual. Problem: Inappropriate medical treatments sometimes cause illness. This “iatrogenic” side effect leads to 20,000 deaths and costs €10 billion per year to the public healthcare system in France alone. Worldwide, it probably leads to more than 1 million deaths and $1 trillion in healthcare costs. Solution: Part of the solution lies in personalized medicine. That is why ExactCure created a Digital Twin. It is a non-intrusive personalized health solution able to predict the efficacy and interactions of drugs based on the specific characteristics of each individual (gender, age, weight, etc.) in real time. This electronic support (simulation, alerts, notification) will augment and secure the therapy. Our solution comes as an App for the patient’s everyday life, and as a SaaS dashboard for the health professional.
Wellness and Spa
Exercise and Fitness
Mobile App Development
Software
Healthcare
Biotechnology

2017

Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in the beautiful city of Innsbruck. We strive to develop new treatments for challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.
Biotechnology

2021

Anjarium Biosciences AG is a genetic medicines company focused on creating and delivering a new generation of targeted gene therapies to patients. Anjarium’s versatile platform builds on novel therapeutic payloads and delivery technologies, with the aim to unlock the full potential of gene therapy.
Pharmaceutical
Biotechnology

2016

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York. *Reach out to us* Email: hello@benevolent.ai Careers: Careers@benevolent.ai Twitter: @benevolent_ai Website: benevolent.com
Machine learning
Artificial Intelligence
Big Data and BI
Software
Pharmaceutical
Biotechnology

2013

Bionema is a leading biopesticide technology developer. We develop and provide chemical free, pest management solutions for the Horticulture, Turf & Amenity, Landscaping & Forestry, and Public Health sectors. With over 30 years' experience in research, development and commercialisation of biopesticides, we have a robust patent portfolio, and we have collected a library of more than a hundred commercially-viable microorganisms for pipeline candidates. Our formulation technologies can give biopesticides higher virulence, stability and spore yields, wider host ranges and higher kill rates. Our products include biopesticides, biostimulants, biofertilisers, efficacy boosters, biocides and pest monitoring traps. If you are interested in using these products, talk to one of our experts about the ones most suited to your needs, and how to use them most effectively. We work with exceptional researchers within universities and private companies around the world to develop natural products that use microorganisms and natural plant chemicals to manage insect pests, reducing the use of synthetic pesticides that can be harmful to people and the planet. If you are looking to collaborate to innovate, then look no further – Bionema can help! As well as developing novel products, Bionema supports researchers, developers and manufacturers of biopesticide products with: - Strain identification, selection and improvement - Production, formulation and application - Analytical and R&D solutions - Quality assessment of biological products - Supporting registration of biocontrol agents - Product efficacy testing - Knowledge transfer Bionema is based in Swansea University with a highly experienced team and access to well-equipped GEP accredited laboratories.
IT Services
Farming Services
IT Consulting Services
CRM
Biotechnology
Agriculture

2012

The World BioProtection Forum (WBF) is a non-profit organisation for encouraging collaboration between the biocontrol industry and academia in the AgriTech sector. Our goal is to ensure the successful development and commercialisation of biocontrol products, by helping our members to overcome challenges and leverage opportunities in a post-COVID, post-Brexit world. Our mission is to bridge the gap between academia and industry globally to ensure the successful development and commercialisation of biocontrol products. WBF connects innovators, entrepreneurs, researchers, manufacturers and distributors operating in the biocontrol sector.
Biotechnology

2019

We specialize in the creation of AI-powered imaging biomarkers to enable precision medicine for better treatment decisions. Since launching as a spin-out from the University of Oxford in 2010, we have developed award-winning, AI-powered imaging biomarkers and software solutions, assisting physicians across the world to make better life-saving decisions.
Medical Equipment and Services
Health and Medical Products
Machine learning
Artificial Intelligence
Software
Medical
Biotechnology

2010

C4Diagnostics is a French-based biotech specialized in the development of in vitro diagnostic (IVD) tests for human infectious diseases C4Diagnostics' strategy for the better management of Human infectious diseases, is to develop game changing IVD tests which are significantly faster than standard methods whilst maintaining comparable or better performance. Its portfolio currently focuses on the diagnosis of Covid-19 (C4Covid-19), Legionnaires’ Disease (C4Legio LFA), urinary tract infections (C4UTI) and the development of antimicrobial susceptibility tests (C4AST). C4Diagnostics also has a business unit dedicated to environmental diagnostics, called C4Environment. It provides services for the detection of SARS-CoV-2 and other pathogens in the environment (wastewater, air, surface) and has contributed to several Covid-19 surveillance and prevention campaigns since the beginning of the pandemic. With its rapid and highly sensitive IVD tests, C4Diagnostics ambitions to become one of the main actors in the diagnosis of human infectious diseases field, by giving medical labs and healthcare professionals sensible and reliable diagnostic information in a timely manner. The game changing diagnostic solutions developed by C4Diagnostics are a leverage to fight against antibiotic resistance and curb infectious disease epidemics. contact@C4Diagnostics.com
Biopharma
Biotechnology

2017

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry. C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m. The Company was founded as a spin-out from the University of Manchester. t has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. Website: www.c4xdiscovery.com Twitter: @C4XDiscovery
Pharmaceutical
Biotechnology
Life Science

2008

To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial. Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages. By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.). For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions. CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.
Pharmaceutical
Biotechnology
Therapeutics

2011

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.
Healthcare
Biotechnology

2014

Carocell Bio is revolutionising the treatment of skin-related inflammatory conditions with its peptide-based, next-generation approach to promoting healthier skin. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options to patients. This includes treating and preventing AD (eczema) and delaying skin ageing – a process strongly associated with inflammation. Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options to patients. This includes treating and preventing AD (eczema) and delaying skin ageing – a process strongly associated with inflammation. Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use.
Biotechnology

2018

Cambridge Cancer Genomics (CCG.ai) are on a mission to ensure that each patient has the right drug, at the right time, to beat their cancer. We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.
Biotechnology

2016

CUBIQ FOODS | Transforming the future of nutrition We are on a mission to improve nutrition around the world. Everything we do is focused on radically improving sustainability, health and nutritional profile, with affordability in mind. We also prioritize the consumers’ organoleptic experience across as many products as possible. As an international food tech company, we combine our scientific knowledge and expertise with the latest advances to provide an innovative range of alternative fats. We lead in three distinct processes; a novel oil/water emulsion, Omega-3 micro-encapsulation techniques, and the first cell-culture platform for specialty fats (cell-based Omega-3). Our solutions to the food industry support the development of high-quality processed food. We achieve this by reducing animal and saturated fats while retaining flavor and texture. We deliver health and nutritional benefits and reduce the calorie content. Our innovative platforms can tune for hardness, texture, and flavor as well as fat content in bespoke product applications. We produce and sell at scale and license production to select producers worldwide. Let’s change food from the inside!
Food Manufacturing
Food Vendors
Beverage Production and Manufacturing
Robotics
Biotechnology

2019

CV6 Therapeutics is an early stage drug development company focused on the discovery, development and commercialization of novel combination therapies for the treatment of cancer. For further investment questions or opportunities please contact: information@cv6t.com
Manufacturing
Pharmaceutical
Healthcare
Biotechnology

2014

Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.
Pharmaceutical
Biotechnology

2014

Deciphex is focused on the development of software applications for preclinical/toxicologic pathology that improve productivity and help pathologists focus on the critical content. The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload. We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.
Health Centers
Health and Medical Products
Artificial Intelligence
Software
Biotechnology

2017

Elsa Science strives to contribute to a future where chronic disease is minimized. Where people who are diagnosed can reach optimal health sooner and live a new life faster, and to its full potential. Elsa Science was established in 2017 by a team of influential scientists and award winning designers who have a passion to improve the health of people living with chronic disease. Driven by science, self-reported patient data, and individualized care, and through meaningful content and design, Elsa Science aims to make science accessible and put it in the hands of the people living with a chronic disease. Providing motivation and education through two tools - the Elsa Science Self-care app and Clinical Dashboard, bring patients and families closer together with healthcare providers through seamless data sharing. Our digital solution provides a powerful communication tool for a greater good, to better manage the illness, improve healthcare, and empower the individual to proactively self-care.
Health Centers
Mental Health Care
Exercise and Fitness
Mobile App Development
Personal Health
Medical
Healthcare

2017

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.
Health Centers
Health and Medical Products
Healthcare
Biotechnology

2017

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.
Pharmaceutical
Biopharma
Biotechnology

2006

Feedect is a leading company in the sustainable food industry, committed to producing high-quality proteins from insects. By leveraging the exceptional nutritional value of insects and their low environmental footprint, Feedect is transforming the way we feed the world. Our innovative production processes allow us to create a wide range of insect-based products, including protein powders, which are rich in essential amino acids, vitamins, minerals and natural prebiotic compounds. At Feedect, we believe that sustainable food production is key to preserving our planet and securing a better future for generations to come. We are proud to be at the forefront of this movement, providing healthy and sustainable food options that contribute to a more responsible and ethical food system. Join us in our mission to create a more sustainable food future. Follow our page to stay up to date on our latest developments, products and initiatives.
Pet Food
Farming Services
Food Processing
Animal Feed
Nutrition
Sustainability
Biotechnology

2018

Flash Therapeutics is a World-class CDMO expert in lentiviral vector manufacturing : With our continuum from research to the clinic we support you throughout your projects from R&D to GMP grade. We provide purified and highly concentrated particles from small scale to large scale with the same vector specifications. Flash Therapeutics provides both integrative lentiviral vectors and non-integrative LentiFlash® particles. Lentiviral vectors : Conventional lentiviral vectors, which lead to DNA integrated into the genome, are a leading delivery method for applications which require a stable and long-term gene expression. Ideal for Gene Therapy and Immunotherapy. LentiFlash® particles : LentiFlash® combines a transient expression with a safe and efficient RNA delivery. This proprietary technology allows the delivery of multiple RNA species, without any genomic scar. Ideal for Regenerative Medicine, Gene Editing and Vaccination / Immunotherapy studies Contact us to design your project !
Medical
Healthcare
Biotechnology

2005

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit. Twitter: @fluidicanalytic
Biotechnology
Life Science

2013

IVF Bioscience aims to help develop the animal IVF market by improving yields through higher success rates. Using the IVF Bioscience media systems, laboratories benefit from our extensive portfolio of knowledge by achieving higher blastocyst rates, more robust blastocysts and thereby higher pregnancy rates.
Biotechnology

2015

Kynos Therapeutics is poised to bring a new generation of potent first-in-class KMO inhibitors to the market - ready to impact on unmet medical needs. Kynos Therapeutics Ltd. is a Private Limited Company Registered in England and Wales, Company number 12501037
Manufacturing
Medical
Healthcare
Biotechnology
Therapeutics

2020

List of Biotechnology companies in Europe

Company Name

Location

Category

Employees

Website

Nantes, France

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://www.ai4r.com/

Helsinki, Finland

Health and Medical
+3
Health and Medical, Information Technology, Business Services, Science and Engineering

50-100

https://www.aiforia.com/

Dublin, Ireland

Health and Medical
+1
Health and Medical, Science and Engineering

200-500

https://www.alkermes.com/

Rotterdam, The Netherlands

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://www.allerotherapeutics.com/

Madrid, Spain

Health and Medical
+1
Health and Medical, Science and Engineering

30-50

https://amadix.com/

Vienna, Austria

Science and Engineering
+1
Science and Engineering, Health and Medical

10-20

https://www.apeiron-biologics.com/

Lund, Sweden

Science and Engineering
Science and Engineering

2-10

https://apoglyx.com/

Madrid, Spain

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://aptatargets.com/

Paris, France

Information Technology
+2
Information Technology, Health and Medical, Science and Engineering

30-50

https://www.aqemia.com/

Valencia, Spain

Science and Engineering
Science and Engineering

10-20

https://www.arthexbiotech.com/

Lund, Sweden

Science and Engineering
+1
Science and Engineering, Health and Medical

10-20

https://www.asgardthx.com/

Munich, Germany

Health and Medical
+1
Health and Medical, Science and Engineering

1000-5000

https://atai.life/

Dortmund, Germany

Environment
+1
Environment, Science and Engineering

2-10

https://bfab.bio/

Edinburgh, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://www.biocaptiva.com/

Marseille, France

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://biocellvia.com/

Paris, France

Electronics
+2
Electronics, Information Technology, Science and Engineering

30-50

https://www.biomemory.com/

Lyon, France

Health and Medical
+2
Health and Medical, Science and Engineering, Sales and Marketing

20-30

https://bioxis.com/

Helsinki, Finland

Health and Medical
+1
Health and Medical, Science and Engineering

200-500

https://blueprintgenetics.com/

Manchester, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://aehinnovativehydrogel.com/

London, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

100-150

https://www.relationrx.com/

Stockholm, Sweden

Manufacturing and Industry
+2
Manufacturing and Industry, Energy, Science and Engineering

50-100

https://enginzyme.com/

Glasgow, United Kingdom (UK)

Information Technology
+4
Information Technology, Business Services, Food and Beverages, Design Services, Science and Engineering

50-100

https://www.3fbio.com/newsletter/

Lyon, France

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

https://erytech.com/

Vienna, Austria

Beauty and Personal Care
+2
Beauty and Personal Care, Health and Medical, Science and Engineering

10-20

https://www.eucodis-enzymes.com/

Hamburg, Germany

Health and Medical
+1
Health and Medical, Science and Engineering

5000+

https://www.evotec.com/en

Nice, France

Beauty and Personal Care
+4
Beauty and Personal Care, Sport and Recreation, Information Technology, Health and Medical, Science and Engineering

2-10

https://www.exactcure.com/

Innsbruck, Austria

Science and Engineering
Science and Engineering

2-10

https://www.angios-bio.com/

Schlieren, Switzerland

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://www.anjarium.com/

London, United Kingdom (UK)

Information Technology
+2
Information Technology, Health and Medical, Science and Engineering

200-500

about:blank

Swansea, United Kingdom (UK)

Information Technology
+3
Information Technology, Agriculture and Livestock, Business Services, Science and Engineering

2-10

https://bionema.com/

Swansea, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://www.worldbioprotectionforum.com/

Oxford, United Kingdom (UK)

Health and Medical
+2
Health and Medical, Information Technology, Science and Engineering

50-100

https://www.brainomix.com/

Marseille, France

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://www.c4diagnostics.com/

Manchester, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://www.c4xdiscovery.com/

Lyon, France

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://www.calixar.com/

Brussels, Belgium

Health and Medical
+1
Health and Medical, Science and Engineering

30-50

https://precirix.com/

Chester, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://carocellbio.com/

Cambridge, United Kingdom (UK)

Science and Engineering
Science and Engineering

10-20

https://dantelabs.co.uk/

Barcelona, Spain

Food and Beverages
+2
Food and Beverages, Information Technology, Science and Engineering

30-50

https://www.cubiqfoods.com/

Belfast, United Kingdom (UK)

Manufacturing and Industry
+2
Manufacturing and Industry, Health and Medical, Science and Engineering

2-10

http://www.cv6t.com/

Bergen, Norway

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://www.cytovation.com/

Dublin, Ireland

Health and Medical
+2
Health and Medical, Information Technology, Science and Engineering

200-500

https://www.deciphex.com/

Stockholm, Sweden

Health and Medical
+3
Health and Medical, Sport and Recreation, Information Technology, Science and Engineering

10-20

https://www.elsa.science/en/

Stockholm, Sweden

Health and Medical
+1
Health and Medical, Science and Engineering

30-50

https://www.elypta.com/

Cambridge, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://f-star.com/

Valencia, Spain

Pets and Animals
+5
Pets and Animals, Agriculture and Livestock, Food and Beverages, Health and Medical, Environment, Science and Engineering

10-20

https://feedect.com/

Toulouse, France

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

https://www.flashtherapeutics.com/web/flash-therapeutics/2-home.php

Cambridge, United Kingdom (UK)

Science and Engineering
Science and Engineering

50-100

https://www.fluidic.com/

Falmouth, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://ivfbioscience.com/

Edinburgh, United Kingdom (UK)

Manufacturing and Industry
+2
Manufacturing and Industry, Health and Medical, Science and Engineering

2-10

http://www.kynostx.com/

100/480 results

Frequently asked questions

Updated 23 October 2026

What is Enterprise League?

Enterprise League is a free business directory that helps buyers find the right company by sector and country. Every company has a profile showing what it does, what it offers and how to get in touch.

Is it free to list my company?

Yes, and it stays free: no card, no paid tier. Your profile appears in search results and category pages, can show up to 20 products and services, and lets buyers message you or ask for a quote.

How does verification work, and what does it cost?

Verifying your company is free. Confirm a code we email to an address at your company’s website, or send a company registration document for our team to check, and the verified badge appears on your profile. To show the badge in the directory and search results as well, take out a subscription: the first 14 days are free, and the price is on our pricing page.

Where does the company information come from?

Most profiles are built from public sources, such as official company registers. Claim your company’s profile to correct its details and add your own.

How do I claim or correct my company’s profile?

Open your company’s profile and choose Claim Profile. If you use an email address at your company’s website, a 6-digit code makes the profile yours at once; otherwise our team reviews your request, usually within a few days. Spotted a mistake on a company that isn’t yours? Tell us through our contact page.